The stock price of Cg Oncology Inc (NASDAQ: CGON) has jumped by 8.55 compared to previous close of 25.95. Despite this, the company has seen a gain of 5.43% in its stock price over the last five trading days. globenewswire.com reported 2025-02-26 that IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to present at the TD Cowen 45th Annual Health Care Conference in Boston, MA on Wednesday, March 5, 2025, at 11:10 am ET.
Is It Worth Investing in Cg Oncology Inc (NASDAQ: CGON) Right Now?
The stock has a 36-month beta value of 0.86. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CGON is 46.13M, and at present, short sellers hold a 15.17% of that float. On March 14, 2025, the average trading volume of CGON was 667.87K shares.
CGON’s Market Performance
CGON stock saw an increase of 5.43% in the past week, with a monthly gain of 0.61% and a quarterly increase of -16.41%. The volatility ratio for the week is 4.27%, and the volatility levels for the last 30 days are 5.66% for Cg Oncology Inc (CGON). The simple moving average for the last 20 days is 6.20% for CGON’s stock, with a simple moving average of -14.56% for the last 200 days.
Analysts’ Opinion of CGON
UBS, on the other hand, stated in their research note that they expect to see CGON reach a price target of $60. The rating they have provided for CGON stocks is “Buy” according to the report published on October 24th, 2024.
RBC Capital Mkts gave a rating of “Outperform” to CGON, setting the target price at $66 in the report published on September 23rd of the previous year.
CGON Trading at -0.70% from the 50-Day Moving Average
After a stumble in the market that brought CGON to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.05% of loss for the given period.
Volatility was left at 5.66%, however, over the last 30 days, the volatility rate increased by 4.27%, as shares sank -0.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.82% lower at present.
During the last 5 trading sessions, CGON rose by +5.78%, which changed the moving average for the period of 200-days by -13.59% in comparison to the 20-day moving average, which settled at $26.53. In addition, Cg Oncology Inc saw -1.78% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CGON starting from POST LEONARD E, who sale 1,000 shares at the price of $28.61 back on Feb 18 ’25. After this action, POST LEONARD E now owns 0 shares of Cg Oncology Inc, valued at $28,610 using the latest closing price.
POST LEONARD E, the Director of Cg Oncology Inc, sale 1,000 shares at $29.66 during a trade that took place back on Jan 13 ’25, which means that POST LEONARD E is holding 0 shares at $29,660 based on the most recent closing price.
Stock Fundamentals for CGON
Current profitability levels for the company are sitting at:
- -139.69 for the present operating margin
- 0.98 for the gross margin
The net margin for Cg Oncology Inc stands at -105.78. The total capital return value is set at -0.18.
Based on Cg Oncology Inc (CGON), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -250.38.
Currently, EBITDA for the company is -55.43 million with net debt to EBITDA at 0.45. When we switch over and look at the enterprise to sales, we see a ratio of 3072.49. The receivables turnover for the company is 4.99for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 35.32.
Conclusion
To sum up, Cg Oncology Inc (CGON) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
